CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Patient Input

This page lists Common Drug Review (CDR) drug applications received by CADTH and the deadlines for filing patient group input for each drug. For more information about how to provide input, please visit the CDR Patient Input page

TBC (filgotinib )

Indications: Arthritis, Rheumatoid

Call For Patient Input: July 6, 2020

Patient Input Closed: August 25, 2020

Ofev (nintedanib)

Indications: chronic fibrosing interstitial lung diseases

Call For Patient Input: June 25, 2020

Patient Input Closed: August 17, 2020

pdp-levETIRAcetam (Levetiracetam )

Indications: Epilepsy

Call For Patient Input: June 17, 2020

Patient Input Closed: August 7, 2020

Hemlibra (emicizumab)

Indications: Bleeding prevention, hemophilia A

Call For Patient Input: June 2, 2020

Patient Input Closed: July 22, 2020

Kynmobi (apomorphine hydrochloride)

Indications: Parkinson’s disease

Call For Patient Input: May 29, 2020

Patient Input Closed: July 20, 2020

Zolgensma (onasemnogene abeparvovec )

Indications: Spinal muscular atrophy (SMA), pediatrics

Call For Patient Input: May 26, 2020

Patient Input Closed: July 15, 2020